DOP2017000081A - NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA aVß6 - Google Patents

NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA aVß6

Info

Publication number
DOP2017000081A
DOP2017000081A DO2017000081A DO2017000081A DOP2017000081A DO P2017000081 A DOP2017000081 A DO P2017000081A DO 2017000081 A DO2017000081 A DO 2017000081A DO 2017000081 A DO2017000081 A DO 2017000081A DO P2017000081 A DOP2017000081 A DO P2017000081A
Authority
DO
Dominican Republic
Prior art keywords
avß6
integrina
new
antagonist compounds
acid
Prior art date
Application number
DO2017000081A
Other languages
English (en)
Inventor
Andrew Anderson Niall
Martin Pritchard John
Howard James Campbell-Crawford Matthew
Mary Redmond Joanna
Paul Hancock Ashley
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of DOP2017000081A publication Critical patent/DOP2017000081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula (I): que es ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo.
DO2017000081A 2014-09-26 2017-03-23 NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA aVß6 DOP2017000081A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417002.1A GB201417002D0 (en) 2014-09-26 2014-09-26 Novel compound

Publications (1)

Publication Number Publication Date
DOP2017000081A true DOP2017000081A (es) 2017-04-30

Family

ID=51901158

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000081A DOP2017000081A (es) 2014-09-26 2017-03-23 NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA aVß6

Country Status (36)

Country Link
US (3) US9956209B2 (es)
EP (2) EP3428167A1 (es)
JP (1) JP6611799B2 (es)
KR (1) KR101998000B1 (es)
CN (1) CN107074848B (es)
AR (1) AR101994A1 (es)
AU (1) AU2015320858B2 (es)
BR (1) BR112017006251A2 (es)
CA (1) CA2962315A1 (es)
CL (1) CL2017000705A1 (es)
CO (1) CO2017002714A2 (es)
CR (1) CR20170112A (es)
CY (1) CY1121071T1 (es)
DK (1) DK3197892T3 (es)
DO (1) DOP2017000081A (es)
EA (1) EA031481B1 (es)
ES (1) ES2690748T3 (es)
GB (1) GB201417002D0 (es)
HR (1) HRP20181796T1 (es)
HU (1) HUE041827T2 (es)
IL (1) IL250592A0 (es)
JO (1) JO3413B1 (es)
LT (1) LT3197892T (es)
MA (1) MA40580B1 (es)
MX (1) MX2017003948A (es)
PE (1) PE20170502A1 (es)
PH (1) PH12017500361A1 (es)
PL (1) PL3197892T3 (es)
PT (1) PT3197892T (es)
RS (1) RS58000B1 (es)
SG (1) SG11201701183YA (es)
SI (1) SI3197892T1 (es)
TW (1) TW201629056A (es)
UA (1) UA119181C2 (es)
UY (1) UY36314A (es)
WO (1) WO2016046225A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
MA46746A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
EA038164B1 (ru) 2016-11-08 2021-07-16 Бристол-Маерс Сквибб Компани 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v
MA46744A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
DK3538528T3 (da) 2016-11-08 2021-02-15 Bristol Myers Squibb Co Pyrrolamider som alpha v-integrinhæmmere
US10696672B2 (en) * 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11332498B2 (en) 2017-03-17 2022-05-17 Technische Universitat Munchen Ligands for integrin αVβ8, synthesis and uses thereof
KR20200084879A (ko) 2017-11-07 2020-07-13 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 피롤로피라진 유도체
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
AR116036A1 (es) * 2018-08-29 2021-03-25 Morphic Therapeutic Inc DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6
WO2020047208A1 (en) * 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047207A1 (en) * 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP4086254A1 (en) 2018-08-29 2022-11-09 Morphic Therapeutic, Inc. Integrin inhibitors
US20210347898A1 (en) * 2018-10-09 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
KR20210099066A (ko) * 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
DE69829996T2 (de) 1997-12-17 2006-02-23 Merck & Co., Inc. (A New Jersey Corp.) Integrin-rezeptor-antagonisten
SK17442001A3 (sk) 1999-06-02 2002-03-05 Merck & Co., Inc. Deriváty kyseliny nonánovej, farmaceutický prostriedok s ich obsahom a ich použitie
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
JP2003510360A (ja) * 1999-10-04 2003-03-18 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
CZ20021508A3 (cs) 1999-11-08 2002-10-16 Merck & Co., Inc. Způsob výroby imidazolidinonových derivátů
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
ATE353219T1 (de) 2000-07-26 2007-02-15 Merck & Co Inc Alpha v integrin-rezeptor-antagonisten
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
JP2004517853A (ja) 2001-01-03 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド 歯周病の治療方法及び治療用組成物
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
BRPI0308585B8 (pt) 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US20050043344A1 (en) 2002-12-20 2005-02-24 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists derivatives
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
ES2446417T3 (es) 2007-03-23 2014-03-07 Amgen Inc. Derivados de quinolina o quinoxalina sustituidos en 3 y su uso como inhibidores de fosfatidilinositol 3-cinasa (PI3K)
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
CL2017000705A1 (es) 2017-11-03
UA119181C2 (uk) 2019-05-10
JP2017528507A (ja) 2017-09-28
LT3197892T (lt) 2018-12-10
SI3197892T1 (sl) 2018-12-31
AU2015320858B2 (en) 2018-10-18
EA201790715A1 (ru) 2017-07-31
US20180271845A1 (en) 2018-09-27
ES2690748T3 (es) 2018-11-22
UY36314A (es) 2016-04-29
CN107074848A (zh) 2017-08-18
EP3197892B1 (en) 2018-09-05
PL3197892T3 (pl) 2019-05-31
GB201417002D0 (en) 2014-11-12
IL250592A0 (en) 2017-04-30
KR20170055489A (ko) 2017-05-19
PH12017500361B1 (en) 2017-07-17
DK3197892T3 (en) 2018-11-26
CA2962315A1 (en) 2016-03-31
CY1121071T1 (el) 2019-12-11
MX2017003948A (es) 2017-06-26
HUE041827T2 (hu) 2019-05-28
HRP20181796T1 (hr) 2018-12-28
SG11201701183YA (en) 2017-04-27
KR101998000B1 (ko) 2019-07-08
PE20170502A1 (es) 2017-04-27
CO2017002714A2 (es) 2017-06-30
BR112017006251A2 (pt) 2017-12-12
JP6611799B2 (ja) 2019-11-27
EP3428167A1 (en) 2019-01-16
EP3197892A1 (en) 2017-08-02
TW201629056A (zh) 2016-08-16
RS58000B1 (sr) 2019-01-31
US9956209B2 (en) 2018-05-01
JO3413B1 (ar) 2019-10-20
EA031481B1 (ru) 2019-01-31
MA40580A (fr) 2017-08-02
US20170290817A1 (en) 2017-10-12
WO2016046225A1 (en) 2016-03-31
AU2015320858A1 (en) 2017-03-09
US10342783B2 (en) 2019-07-09
CR20170112A (es) 2017-05-26
US20190275016A1 (en) 2019-09-12
CN107074848B (zh) 2019-11-01
MA40580B1 (fr) 2018-09-28
PH12017500361A1 (en) 2017-07-17
AR101994A1 (es) 2017-01-25
PT3197892T (pt) 2018-12-12

Similar Documents

Publication Publication Date Title
DOP2017000081A (es) NUEVOS COMPUESTOS ANTAGONISTAS DE INTEGRINA aVß6
AR101995A1 (es) COMPUESTOS ANTAGONISTAS DE INTEGRINA avb6
UY35505A (es) ANTAGONISTAS DE LA INTEGRINA aVß6.
CY1118212T1 (el) Παραγοντες οι οποιοι τροποποιουν την s1p
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
RS54730B1 (sr) Inhibitori beta sekretaze
UY34257A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alquiniloxi-etil}-1h-[1,2,4]triazol sustituidos
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR094997A1 (es) Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
CL2018001067A1 (es) Compuesto piranodipiridínico.
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
ES2571577T3 (es) Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2
EA201692139A1 (ru) Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
ZA202003028B (en) Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
PE20171259A1 (es) Compuestos
EA201690593A1 (ru) Новые соединения мочевины
CY1122343T1 (el) Μεθοδοι για την κατασκευη παραγωγων ινδαζολιου
AR099304A1 (es) Polimorfos cristalinos de la base libre del 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehído